explore -WSS

explore

author：fashion 2025-09-03 03:39:52 - browse：29646

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Microsoft's Peter Lee: Generative AI could help doctors be more human

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

State of the Union pitch: Bigger Medicare drug price negotiations

Smaller biotechs seek to piggyback on weight loss drug boom

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Is there really a nursing shortage in the U.S.?

STAT Summit: The economic case for universal basic health care

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare drug price negotiation continues, as pharma counteroffers

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Readout Newsletter: Biotech news today

ChatGPT in medicine: STAT answers readers' burning questions

Cassava Sciences’ Alzheimer’s clinical trials should be halted

ChatGPT in medicine: STAT answers readers' burning questions

Health tech investors get more selective as pandemic boom fades

leisure time

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Lack of health data on LGBTQ+ people has serious consequences

Change Healthcare: What is it, why does its cyberattack matter?

Roche drug slashes death risk in early

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

For AI in health care standards, federal regulators join with industry group

hotspot

hotspot

explore

focus